{"groups":[{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"FG000","title":"Cohort 1- CFZ 20 mg/m^2 (Day 1,2)"},{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"FG001","title":"Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)"},{"description":"Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT)\n\n•Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:\n\nCohort 1: add CFZ 20 mg/m\\^2 intravenous (IV) on days +1, +2\n\nCohort 2 : add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9\n\nCohort 3: add CFZ 20 mg/m\\^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m\\^2 IV given on days 42-43 then CFZ 56 mg/m\\^2 IV given on days 49-50, 56-57, then on days 70.","id":"FG002","title":"Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Principal Investigator discretion"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study did not progress to the phase II portion. The study was closed prematurely because the investigator left the National Institutes of Health."}